Alaunos Therapeutics

Alaunos Therapeutics is a clinical-stage biopharmaceutical company that has repositioned its pipeline around orally administered, non-hormonal small-molecule therapeutics for obesity and related metabolic disorders - an approach deliberately distinct from hormone-based and incretin-based treatments such as GLP-1 receptor agonists. The company retains the hunTR TCR discovery platform, which was built to identify T-cell receptors targeting driver mutations in solid tumors and was the basis of its earlier engineered T-cell programs. Alaunos is based in Fort Lauderdale, Florida, and previously operated as ZIOPHARM Oncology before adopting the Alaunos name. Its capital structure is highly dilutive: the company reported approximately $124,000 of cash at June 30, 2026, and has funded operations through repeated registered direct offerings priced at or near the prevailing market price under its shelf registration.